Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma
- PMID: 33827453
- PMCID: PMC8028749
- DOI: 10.1186/s12885-021-08103-0
Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma
Abstract
Background and aims: Studies suggest that mutations in the CTNNB1 gene are predictive of response to immunotherapy, an emerging therapy for advanced hepatocellular carcinoma (HCC). Analysis of circulating tumor DNA (ctDNA) offers the possibility of serial non-invasive mutational profiling of tumors. Combining tumor tissue and ctDNA analysis may increase the detection rate of mutations. This study aimed to evaluate the frequency of the CTNNB1 p.T41A mutation in ctDNA and tumor samples from HCC patients and to evaluate the concordance rates between plasma and tissue. We further evaluated changes in ctDNA after various HCC treatment modalities and the impact of the CTNNB1 p.T41A mutation on the clinical course of HCC.
Methods: We used droplet digital PCR to analyze plasma from 95 patients and the corresponding tumor samples from 37 patients during 3 years follow up.
Results: In tumor tissue samples, the mutation rate was 8.1% (3/37). In ctDNA from HCC patients, the CTNNB1 mutation rate was 9.5% (9/95) in the pre-treatment samples. Adding results from plasma analysis to the subgroup of patients with available tissue samples, the mutation detection rate increased to 13.5% (5/37). There was no difference in overall survival according to CTNNB1 mutational status. Serial testing of ctDNA suggested a possible clonal evolution of HCC or arising multicentric tumors with separate genetic profiles in individual patients.
Conclusion: Combining analysis of ctDNA and tumor tissue increased the detection rate of CTNNB1 mutation in HCC patients. A liquid biopsy approach may be useful in a tailored therapy of HCC.
Keywords: Circulating tumor DNA; Droplet digital PCR; Hepatocellular carcinoma; Molecular pathology; Predictive biomarkers.
Conflict of interest statement
The authors have nothing to disclose in relation to this manuscript.
Figures
![Fig. 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8028749/bin/12885_2021_8103_Fig1_HTML.gif)
Similar articles
-
Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma.Oncogene. 2021 Jan;40(1):140-151. doi: 10.1038/s41388-020-01519-1. Epub 2020 Oct 23. Oncogene. 2021. PMID: 33097857
-
Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma.Int J Biol Sci. 2020 Mar 5;16(9):1551-1562. doi: 10.7150/ijbs.44024. eCollection 2020. Int J Biol Sci. 2020. PMID: 32226301 Free PMC article. Review.
-
Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma.Eur J Cancer. 2019 Jul;116:56-66. doi: 10.1016/j.ejca.2019.04.014. Epub 2019 Jun 4. Eur J Cancer. 2019. PMID: 31173963
-
Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing.Oncotarget. 2016 Jun 28;7(26):40481-40490. doi: 10.18632/oncotarget.9629. Oncotarget. 2016. PMID: 27248174 Free PMC article.
-
Prospects and challenges of circulating tumor DNA in precision medicine of hepatocellular carcinoma.Clin Exp Med. 2020 Aug;20(3):329-337. doi: 10.1007/s10238-020-00620-9. Epub 2020 Apr 1. Clin Exp Med. 2020. PMID: 32239299 Review.
Cited by
-
Recent Advances in Biosensor Technology for Early-Stage Detection of Hepatocellular Carcinoma-Specific Biomarkers: An Overview.Diagnostics (Basel). 2024 Jul 15;14(14):1519. doi: 10.3390/diagnostics14141519. Diagnostics (Basel). 2024. PMID: 39061656 Free PMC article. Review.
-
Circulating tumor DNA mutation analysis: advances in its application for early diagnosis of hepatocellular carcinoma and therapeutic efficacy monitoring.Aging (Albany NY). 2024 Jul 19;16(14):11460-11474. doi: 10.18632/aging.205980. Epub 2024 Jul 19. Aging (Albany NY). 2024. PMID: 39033781 Free PMC article. Review.
-
ctDNA as a novel and promising approach for cancer diagnosis: a focus on hepatocellular carcinoma.EXCLI J. 2023 Aug 3;22:752-780. doi: 10.17179/excli2023-6277. eCollection 2023. EXCLI J. 2023. PMID: 37720239 Free PMC article. Review.
-
The Use of ctDNA in the Diagnosis and Monitoring of Hepatocellular Carcinoma-Literature Review.Int J Mol Sci. 2023 May 26;24(11):9342. doi: 10.3390/ijms24119342. Int J Mol Sci. 2023. PMID: 37298294 Free PMC article. Review.
-
Updating the Clinical Application of Blood Biomarkers and Their Algorithms in the Diagnosis and Surveillance of Hepatocellular Carcinoma: A Critical Review.Int J Mol Sci. 2023 Feb 21;24(5):4286. doi: 10.3390/ijms24054286. Int J Mol Sci. 2023. PMID: 36901717 Free PMC article. Review.
References
-
- Wallace MC, Preen D, Jeffrey GP, Adams LA. The evolving epidemiology of hepatocellular carcinoma: a global perspective. Expert Rev Gastroenterol Hepatol. 2015;9(6):765–79. 10.1586/17474124.2015.1028363. - PubMed
-
- Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90. 10.1056/NEJMoa0708857. - PubMed
-
- Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66. 10.1016/s0140-6736(16)32453-9. - PubMed
-
- Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894–905. 10.1056/NEJMoa1915745. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous